Nektar And Bristol Hurtle Forward With Experimental Cancer Drug

Nektar Pharmaceuticals and Bristol-Myers Squibb said results for their experimental cancer drug, NKTR-214, pushing forward into late-stage trials testing the medicine against melanoma, renal cell carcinoma, and urothelial cancer.

Source: Forbes.com Healthcare News - June 2, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:NKTR NYSE:BMY Source Type: news